Given the role of FAS/FASLG pathway in carcinogenesis, it is biologically plausible that the rs2234767 and rs1800682 polymorphisms may modulate the risk of CRC by attenuating SP1/STAT1 complex-mediated transcriptional activation of FAS, which in turn dampening FAS apoptotic pathway. Here, STAT1 is linked to colorectal carcinoma.